Use of MVA to treat prostate cancer

• US 8,377,688 B2
• Filed: 08/30/2010
• Issued: 02/19/2013
• Est. Priority Date: 10/18/2007
• Status: Expired due to Fees

• Current Assignee: Bavarian Nordic A/S
• Original Assignee: BN Immunotherapeutics, Inc. (Bavarian Nordic A/S)
• Inventors: Delcayre, Alain, Laus, Reiner, Mandl, Stefanie, Rountree, Ryan Blair, Legrand, Fatema
• Primary Examiner(s): LI, BAO Q
• Application Number:
  US12/871,017
• Publication Number:
  US 20110008386A1
• Time in Patent Office: 904 Days
• Field of Search: None
• US Class Current: 435/320.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/001193 Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
• CPC Class Codes: A61K 39/001194 Prostate specific antigen [PSA]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: C12N 2799/023 where the vector is derived from a poxvirus
• CPC Class Codes: C12N 2799/04 in vivo
• CPC Class Codes: C12N 2830/60 from viruses

Abstract

The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B-and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.

Claims

1. A recombinant modified vaccinia virus Ankara (MVA) expressing a polypeptide comprising a human prostatic acid phosphatase (PAP) antigen, wherein the recombinant MVA virus induces B-cell and T-cell immune responses against the human PAP antigen when administered to a human host.

2. The recombinant MVA virus of claim 1, wherein the MVA virus comprises SEQ ID NO:

2.

3. The recombinant MVA virus of claim 1, wherein the MVA is MVA-Bavarian Nordic (MVA-BN).

4. The recombinant MVA virus of claim 2, wherein the MVA is MVA-BN.

5. The recombinant MVA virus of claim 1, wherein the recombinant MVA virus further expresses a polypeptide comprising a human prostate-specific antigen (PSA) antigen.

6. The recombinant MVA virus of claim 2, wherein the recombinant MVA virus further expresses a polypeptide comprising a human PSA antigen.

7. The recombinant MVA virus of claim 3, wherein the recombinant MVA virus further expresses a polypeptide comprising a human PSA antigen.

8. The recombinant MVA virus of claim 4, wherein the recombinant MVA virus further expresses a polypeptide comprising a human PSA antigen.

9. The recombinant MVA virus of claim 5, wherein the recombinant MVA virus further expresses the nucleotide sequence of SEQ ID NO:

1.

10. The recombinant MVA virus of claim 6, wherein the MVA virus comprises the nucleotide sequence of SEQ ID NO:

1.

11. The recombinant MVA virus of claim 7, wherein the MVA virus comprises the nucleotide sequence of SEQ ID NO:

1.

12. The recombinant MVA virus of claim 8, wherein the MVA virus comprises the nucleotide sequence of SEQ ID NO:

1.

13. An immunogenic composition comprising the recombinant MVA virus of claim 1.

14. An immunogenic composition comprising the recombinant MVA virus of claim 2.

15. An immunogenic composition comprising the recombinant MVA virus of claim 3.

16. An immunogenic composition comprising the recombinant MVA virus of claim 4.

17. An immunogenic composition comprising the recombinant MVA virus of claim 5.

18. An immunogenic composition comprising the recombinant MVA virus of claim 6.

19. An immunogenic composition comprising the recombinant MVA virus of claim 7.

20. An immunogenic composition comprising the recombinant MVA virus of claim 8.

21. A kit for an immunogenic composition of human prostate cancer comprising:

(a) the recombinant MVA of claim 5; and

(b) instructions to administer the recombinant MVA prior to the detection of prostate cancer.

22. A kit for the treatment of human prostate cancer comprising:

(a) the recombinant MVA of claim 5; and

(b) instructions to administer the recombinant MVA to a human prostate cancer patient.

23. A kit for treating a human cancer patient comprising:

(a) the recombinant MVA of claim 5; and

(b) instructions to administer the recombinant MVA prior to, at the same time as, or after treatment with a tumoricidal dose of a taxane.